How does self-measurement for asthma using Vivatmo me compare with other control methods?
Gebauer: The device does not replace a visit with your doctor. Patients are strongly encouraged to get regular medical checkups. The measurements of FeNO values by the physician are often used as a more general assessment of the course of asthma activity or to make an initial diagnosis. The idea behind the FeNO home measurement is to allow closer monitoring and tracking of the disease progression and improve the quality of life of the asthma patient.
Many asthma patients also use peak flow meters at home. These devices measure how well air moves out of the lungs and give patients an indication of the current state of their asthma. Observational studies have shown that FeNO levels often increase before patients experience actual symptoms of an attack or exacerbation, a flare-up and progression of the condition.
In view of this, there is no directly comparable at-home method. Having said that, FeNO levels tend to provide a prognostic value of bronchial provocation, making them suited for asthma management and prevention.
Has the coronavirus pandemic accelerated the use of this device as a telemedicine solution?
Gebauer: The pandemic has prompted many people to postpone or even cancel doctor appointments to minimize the risk of exposure and spread of the disease. During these unprecedented times, patients who already use the Vivatmo me device to measure airway inflammation at home might feel more confident and in control of their asthma while they virtually consult with their physician.
While we are not quite at that stage yet, we fully expect that Vivatmo me has a strong future in remote patient monitoring. Undoubtedly, the pandemic has expedited awareness of telemedicine technology as it pertains to chronic diseases of the respiratory system.